Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).

Witt, M; Grunke, M; Proft, F; Baeuerle, M; Aringer, M; Burmester, G; Chehab, G; Fiehn, C; Fischer-Betz, R; Fleck, M; Freivogel, K; Haubitz, M; Kötter, I; Lovric, S; Metzler, C; Rubberth-Roth, A; Schwarting, A; Specker, C; Tony, H-P; Unger, L; Wassenberg, S; Dörner, T; Schulze-Koops, H

Witt, M; Grunke, M; Proft, F; Baeuerle, M; Aringer, M; Burmester, G; Chehab, G; Fiehn, C; Fischer-Betz, R; Fleck, M; Freivogel, K; Haubitz, M; Kötter, I; Lovric, S; Metzler, C; Rubberth-Roth, A; Schwarting, A; Specker, C; Tony, H-P; Unger, L; Wassenberg, S; Dörner, T; Schulze-Koops, H.

Affiliation

Witt M; 1Division of Rheumatology, Medizinische Klinik und Poliklinik IV, University Hospital Munich, Germany.

Lupus ; 22(11): 1142-9, 2013 Oct.

Article in En | MEDLINE | ID: mdl-24057058

Subject(s)

Antibodies, Monoclonal, Murine-Derived/therapeutic use; Lupus Erythematosus, Systemic/drug therapy; Adult; Antibodies, Monoclonal, Murine-Derived/adverse effects; Cohort Studies; Female; Humans; Male; Off-Label Use; Retrospective Studies; Rituximab

Key words

B lymphocytes; Systemic lupus erythematosus; cohort studies; efficacy; rituximab; safety

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Monoclonal, Murine-Derived / Lupus Erythematosus, Systemic Type of study: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male Language: En Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google